ABT · 8-K · 20261021PR117587

Strategic Business Separation

ABBOTT LABORATORIES · 2026-10-21 · Importance 71 · Surprise 60

Abbott intends to separate its global Nutrition business into an independent, publicly traded company through a tax-free distribution of shares to Abbott shareholders. The Nutrition company is expected to have approximately $8.5 billion in annual sales, about 16,000 employees and 14 manufacturing sites. Following separation, Abbott expects approximately $42 billion in sales and about 106,000 employees, focused on medical devices, biowearables, diagnostics and established medicines. Abbott expects the transaction to be completed by the end of 2027, with both companies pursuing distinct resource-allocation and growth strategies.

Key facts

• The separation is expected to be completed by the end of 2027. source
• Abbott announces its intention to separate its Nutrition business into an independent, publicly traded company. source
• Abbott intends to separate its Nutrition business through a tax-free distribution to Abbott shareholders. source
• The transaction is intended to qualify as a tax-free separation for U.S. federal income tax purposes. source
• Upon completion of the separation, Abbott shareholders will own shares in both Abbott and the independent Nutrition company. source
• The Nutrition company will have about 16,000 employees. source
• Abbott will have about 106,000 employees after the separation. source
• The Nutrition business will continue to operate as part of Abbott throughout the separation process. source